Novo Nordisk’s Longevity Gamble: Can Organ Protection Outweigh a Weakening Core Business?

Novo Nordisk is trying to sell a future beyond weight loss. On the ADA conference stage in New Orleans, CEO Mike Doustdar laid out a vision that stretches from aesthetic medicine to biological age reversal, all powered by the same GLP-1 platform. But with the stock down nearly 48% from last year’s record and a key pipeline contender trailing Eli Lilly, the market is not buying the narrative just yet.

The numbers tell a sobering tale. The shares recently traded at €36.58, well below the 200-day moving average of €41.56, and have shed roughly 18% in 2026 alone. A 15-billion-Danish-krone buyback programme has done little to arrest the slide. By early June, the company had repurchased 18.8 million B-shares for about 5 billion kroner, leaving room for another 10 billion in purchases under the current tranche, which runs until early 2027. Yet the stock remains stuck in the doldrums, hovering just above the year’s low of €30.25.

The operational picture is no brighter. While first-quarter 2026 revenues jumped on the back of a one-time reversal of US provisions, adjusted sales actually shrank by 4% after stripping out that accounting effect. Adjusted operating profit, on a currency-adjusted basis, fell 6%. The competitive pressure in the GLP-1 market, especially from Eli Lilly’s Zepbound, is squeezing Novo’s core business harder than expected.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

That pressure was on full display at the ADA meeting. Novo’s investigational drug CagriSema delivered a 23% weight reduction after 84 weeks in a head-to-head trial, missing the 25.5% bar set by Lilly’s Zepbound. The market took note: the stock barely budged on the data release. However, there was a bright spot. The experimental pill Zenagamtide produced strong Phase 2 results in over 250 patients with type 2 diabetes, yielding 14.6% weight loss at the highest dose with no sign of a plateau. A Phase 3 programme is now slated to begin in the second half of 2026, with readouts not expected before 2028.

Doustdar used the spotlight to pivot the conversation toward longevity. He argued that Semaglutide has effects that go far beyond waistlines. Data presented at the conference suggested the drug reduces the biological age of the heart and kidneys, protecting vital organs before significant weight loss even occurs. Novo Nordisk now positions itself as part of the longevity industry, not merely a diabetes or obesity company.

But clinical validation takes time, and the market is notoriously impatient. The buyback is a tacit admission that management sees the current valuation as cheap, yet it has been unable to create a floor. Until Zenagamtide matures into a commercial product or the longevity thesis generates hard revenue, the shares are likely to remain tethered to the disappointing near-term fundamentals. The next catalyst is the pace of the buyback itself: with over 10 billion kroner still available, the speed of repurchases will be the key metric to watch in the weeks ahead.

Ad

Novo Nordisk Stock: New Analysis - 10 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69511378 |